Table 2.
The results summary of clinical outcomes and analyses.
| Study | Follow-up time (years) | Cut-off value | Sensitivity | Specificity | AUC | Model | Outcome event | Number of events | HR | HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| ≤Cut-off value | >Cut-off value | |||||||||
| Kogame et al. (16) | 1.75 | 0.89 | 60% | 87% | 0.77 | Offline | VOCE | 31/123 (25%) | 22/628 (3.5%) | 2.91 (1.63–5.19) |
| Biscaglia et al. (15) | 2 | 0.91 | 65% | 64% | 0.702 | Offline | VOCE | 34/284 (12%) | 18/487 (3.7%) | 3.37 (1.91–5.97) |
| Tang et al. (17) | 2 | 0.91 | NR | NR | 0.72 | Offline | VOCE | 21/101 (20.8%) | 18/314 (5.7%) | 2.718 (1.347–5.486) |
| Bar et al. (19) | 5 | 0.80 | 23.4% | 97.5% | 0.64 | Offline | VOCE | 13/36 (36.1%) | 74/910 (8.1%) | 3.50 (1.94–6.30) |
| Tang et al. (18) | 1 | 0.94 | 74% | 75% | 0.77 | Offline | VOCE | 20/59 (33.9%) | 7/126 (5.6%) | 6.53 (2.7–15.80) |
| Liu et al. (20) | 1 | 0.89 | NR | NR | 0.74 | Offline | VOCE | 11/36 (30.6%) | 9/133 (6.8%) | 5.94 (2.33–15.09) |
| You et al. (21) | 3 | 0.94 | 89.5% | 69.2% | 0.826 | Offline | TLF | 36/54 (66.7%) | 16/170 (9.4%) | 10.35 (5.09–21.04) |
| Zhang et al. (22) | 2 | 0.92 | 62.2% | 83% | 0.75 | Offline | VOCE | 51/416 (12.4%) | 31/1,811 (1.7%) | 7.59 (4.86–11.9) |
NR, not reported.